Betnovate

How to order Betnovate

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Betnovate on Prescriptsy

Betnovate is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Betnovate is a brand-name topical corticosteroid manufactured by GlaxoSmithKline, containing betamethasone valerate 0.1% as its active ingredient.

Classified as a potent corticosteroid in the British National Formulary (BNF), Betnovate is one of the most widely prescribed topical steroids in UK primary care.

It is indicated for the treatment of moderate to severe inflammatory skin conditions including atopic eczema, psoriasis, contact dermatitis, seborrhoeic dermatitis, and other steroid-responsive dermatoses.

Betnovate is available in multiple formulations to suit different skin types and body sites: cream for moist or weeping areas, ointment for dry or lichenified skin, lotion for large body areas, and a scalp application for inflammatory scalp conditions.

This page provides a comprehensive clinical overview of Betnovate, covering how it works, correct usage, treatment duration, side effects, safety warnings, and how to obtain a prescription in the UK.

Important safety information about Betnovate

Before using Betnovate, be aware of the following key safety points. Betnovate is a prescription-only medicine (POM) in the UK.

• Do not apply Betnovate to skin with untreated bacterial, fungal, or viral infections. Corticosteroids can mask and worsen infections.
• Do not use Betnovate on the face for more than 5 days without dermatologist supervision.
• Keep treatment courses as short as clinically necessary. Prolonged use risks skin thinning, stretch marks, and other local side effects.
• In children, use only under specialist supervision for the shortest effective duration.

What is Betnovate

Betnovate is the original brand of betamethasone valerate 0.1% topical corticosteroid, introduced in the UK in the 1960s and manufactured by GlaxoSmithKline.

It has a long-established safety and efficacy profile and remains a first-choice potent topical corticosteroid for many UK prescribers.

The active ingredient, betamethasone valerate, is a synthetic fluorinated glucocorticoid that exerts potent anti-inflammatory, antipruritic, and vasoconstrictive effects when applied to the skin.

Betnovate is available as: Betnovate Cream (water-miscible base containing cetomacrogol, suitable for moist or weeping areas), Betnovate Ointment (paraffin-based, providing superior hydration and occlusion for dry and scaly conditions), Betnovate Lotion (for application to large areas or hairy skin), and Betnovate Scalp Application (an aqueous-alcoholic solution for inflammatory scalp conditions).

How Betnovate works

Betamethasone valerate penetrates the stratum corneum and binds to intracellular glucocorticoid receptors within skin cells including keratinocytes, fibroblasts, and resident immune cells.

The activated receptor complex enters the cell nucleus and modulates gene transcription, suppressing the production of pro-inflammatory cytokines (interleukins IL-1, IL-6, and TNF-alpha), prostaglandins, and leukotrienes.

This produces multiple beneficial effects: vasoconstriction reduces erythema, reduced capillary permeability decreases oedema, suppression of inflammatory mediators relieves pruritus, and inhibition of leucocyte migration and activation damps the immune response driving eczema and psoriasis.

The combined result is a rapid reduction in redness, swelling, itching, and scaling, allowing the skin barrier to recover.

Betnovate Cream and Betnovate Ointment deliver the same active ingredient concentration (0.1%) but differ in their base.

The cream base includes water and emulsifying agents, making it cosmetically lighter and easier to spread on moist skin.

The ointment base is anhydrous (water-free) paraffin, which provides a more occlusive barrier that enhances drug penetration and skin hydration, making it more effective for dry, thickened, or lichenified skin.

Conditions treated with Betnovate

Atopic eczema

Atopic eczema is a chronic, relapsing inflammatory skin condition affecting up to 20% of children and 10% of adults in the UK.

NICE Clinical Guideline CG57 recommends a stepped approach, with potent topical corticosteroids such as Betnovate used for moderate to severe flares on the trunk and limbs.

Treatment is applied once or twice daily until the flare resolves, then stepped down to a milder preparation or emollient-only maintenance.

Weekend (proactive) therapy with twice-weekly application to previously affected sites may be recommended to reduce flare frequency in severe cases.

Psoriasis

Plaque psoriasis presents as well-demarcated, erythematous plaques with adherent silvery-white scale.

Potent topical corticosteroids are a first-line treatment option for mild to moderate psoriasis, typically used in combination with a vitamin D analogue such as calcipotriol.

NICE CG153 recommends short-term potent corticosteroid treatment of up to 4 weeks for trunk and limb psoriasis, followed by a vitamin D analogue for ongoing maintenance.

Betnovate Scalp Application is commonly prescribed for scalp psoriasis.

Contact dermatitis and other dermatoses

Betnovate is also prescribed for allergic and irritant contact dermatitis, seborrhoeic dermatitis, discoid lupus erythematosus, lichen planus, and other steroid-responsive conditions where a potent corticosteroid is clinically indicated.

The prescriber will assess the diagnosis, severity, and body site before recommending Betnovate over milder alternatives.

How to apply Betnovate correctly

Correct application maximises efficacy and minimises side effects. Wash and dry the affected area.

Squeeze a thin ribbon of cream or ointment along the length of your fingertip from the tip to the first crease.

This is one fingertip unit (FTU), approximately 0.5 g, covering an area the size of two adult palms. Apply in a thin, even layer and rub in gently.

Avoid vigorous rubbing. Wash your hands after application unless the hands are being treated.

Apply Betnovate once or twice daily.

Current evidence, including NICE guidance, suggests that once-daily application is as effective as twice-daily for most patients, with a lower risk of local side effects.

Your prescriber will advise on the appropriate frequency for your condition.

Emollient timing

Emollients are a critical part of managing eczema and psoriasis and should be used regularly alongside Betnovate.

Apply your emollient first, wait at least 20 to 30 minutes to allow absorption, then apply Betnovate to the inflamed area.

Alternatively, apply them at different times of day. Using an emollient immediately before a corticosteroid can dilute the active ingredient and spread it beyond the target area.

Treatment duration

Betnovate is intended for short-term treatment of flares. A typical course lasts 7 to 14 days for eczema and up to 4 weeks for psoriasis.

Continuous use beyond 4 weeks on any single body area should be reviewed by your prescriber.

When the condition is controlled, step down to a milder corticosteroid or emollient-only maintenance.

If your prescriber recommends proactive (weekend) therapy, apply Betnovate to previously affected areas twice weekly to maintain remission.

Side effects of Betnovate

Common local side effects

Mild burning, stinging, or itching at the application site may occur, particularly on first use. These effects are usually transient. Skin dryness may occur, especially with the cream formulation, which can be mitigated by regular emollient use.

Side effects from prolonged use

Extended use of Betnovate beyond recommended durations increases the risk of irreversible local changes: skin atrophy (thinning, fragile skin), striae (stretch marks, particularly in flexural areas), telangiectasia (visible dilated blood vessels), easy bruising, hypopigmentation or hyperpigmentation, and acneiform or rosacea-like eruptions.

These changes are more likely on thin-skinned areas such as the face, eyelids, axillae, and groin.

Systemic side effects

Systemic absorption is minimal with short-term, localised use.

However, widespread application, prolonged treatment, use under occlusion, or application to extensive broken skin can lead to systemic effects including hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushingoid features, hyperglycaemia, and growth retardation in children.

Periocular use carries a risk of raised intraocular pressure and cataract formation.

When to seek medical advice

Contact your GP or NHS 111 if your skin worsens during treatment, if you develop signs of skin infection (increasing redness, warmth, pus, or pain), or if you notice skin thinning or stretch marks.

Report suspected adverse reactions via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk .

Warnings and precautions

Infections

Do not use Betnovate on infected skin unless a suitable antimicrobial is being used concurrently.

Corticosteroids suppress the local immune response and can allow bacterial, fungal, or viral infections to spread.

If infection develops during treatment, add appropriate antimicrobial therapy and consider pausing the corticosteroid until the infection is controlled.

Face and sensitive areas

Do not apply Betnovate to the face for more than 5 days without specialist supervision. Avoid the eyelids due to the risk of glaucoma and cataract.

Thin-skinned flexural areas (axillae, groin, under breasts) absorb corticosteroids more readily and are at increased risk of local side effects.

Children

Potent corticosteroids in children require specialist supervision. Children have thinner skin and a higher body-surface-area-to-weight ratio, increasing the risk of systemic effects. Nappy areas should not be treated with potent corticosteroids.

Pregnancy and breastfeeding

Avoid extensive or prolonged use during pregnancy. Small amounts on limited areas for short durations are generally considered low risk. During breastfeeding, do not apply to the breast before feeding. Consult your prescriber for individualised advice.

Excipient sensitivities

Betnovate Cream contains cetostearyl alcohol and chlorocresol, which may cause contact sensitivity in some individuals. If you develop worsening or new skin irritation that does not match your underlying condition, inform your prescriber, as excipient allergy may be responsible.

How to get a Betnovate prescription in the UK

Betnovate is a prescription-only medicine (POM) in the UK. Your GP will assess your skin condition, confirm the diagnosis, and determine whether a potent corticosteroid is appropriate.

If your eczema or psoriasis is severe or unresponsive to initial treatment, referral to a dermatologist may be recommended.

Authorised online prescribers registered with the General Pharmaceutical Council (GPhC) may also prescribe Betnovate following a structured consultation. All prescriptions are dispensed by registered pharmacies.

The standard NHS prescription charge in England is currently 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Betnovate compared with other topical corticosteroids

Betnovate sits in the potent category of the BNF corticosteroid potency ladder, alongside mometasone furoate 0.1% and betamethasone dipropionate 0.05%.

It is stronger than moderate preparations such as clobetasone butyrate 0.05% (Eumovate) and milder than very potent preparations such as clobetasol propionate 0.05% (Dermovate).

Your prescriber will select the appropriate potency based on the severity of your condition, the body site, and your treatment history.

The goal is always to use the least potent preparation that controls the disease effectively.

Living with inflammatory skin conditions

Long-term skin health depends on consistent daily care beyond topical corticosteroid treatment. Use emollients liberally and frequently, even when the skin appears clear.

Replace standard soap with emollient wash products to protect the skin barrier. Wear loose cotton clothing to reduce irritation. Identify and avoid known triggers.

For eczema, NICE recommends step-up and step-down treatment plans, with patients empowered to self-manage flares using a pre-agreed treatment plan.

For psoriasis, controlled UV exposure and stress management can complement pharmacological treatment.

When to seek urgent medical advice

Contact your GP or NHS 111 if your condition deteriorates rapidly, if you develop widespread erythema and scaling (possible erythroderma), or if signs of infection develop.

Eczema herpeticum (herpes simplex superinfection of eczematous skin) presents with clustered painful blisters and requires urgent antiviral treatment.

Seek emergency care by calling 999 or attending A&E if you develop signs of a severe allergic reaction including swelling of the face, lips, or throat, or difficulty breathing.

Sources

• Betnovate Cream, Summary of Product Characteristics (EMC)
• Betamethasone, British National Formulary (BNF)
• NICE CG57: Atopic eczema in under 12s
• NICE CG153: Psoriasis, assessment and management
• Topical corticosteroids, NHS
• MHRA Yellow Card Scheme